Your shopping cart is currently empty

SHP2-IN-44 (Compound 26) is an allosteric, orally active inhibitor of SHP2, with an IC50 of 27 nM. It effectively inhibits ERK phosphorylation with an IC50 of 299 nM and exhibits no off-target hERG activity. SHP2-IN-44 shows broad-spectrum anticancer activity, including efficacy against juvenile myelomonocytic leukemia, neuroblastoma, and breast cancer. It is also useful for research in Noonan syndrome, LEOPARD syndrome, and cancer.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | SHP2-IN-44 (Compound 26) is an allosteric, orally active inhibitor of SHP2, with an IC50 of 27 nM. It effectively inhibits ERK phosphorylation with an IC50 of 299 nM and exhibits no off-target hERG activity. SHP2-IN-44 shows broad-spectrum anticancer activity, including efficacy against juvenile myelomonocytic leukemia, neuroblastoma, and breast cancer. It is also useful for research in Noonan syndrome, LEOPARD syndrome, and cancer. |
| Molecular Weight | 471.98 |
| Formula | C22H23ClFN7S |
| Cas No. | 2818955-47-2 |
| Smiles | C(N)[C@]1([C@@]2([C@]1(CCN(C2)C3=NC(N)=C(SC=4C(Cl)=C(N)N=CC4)N=C3)[H])[H])C5=C(F)C=CC=C5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.